Key facts
- 52-week range (closes)
- $569.17 – $852.03 Lowest close Oct 16, 2025, highest Sep 2, 2026; 251 daily closes to Oct 13, 2026 from Dalsna Finance's price archive
- Fiscal year ends
- December Fiscal 2025 ended Dec 31, 2025, from SEC filings
- In the S&P 500 since
- Apr 30, 2013 · All S&P 500 changes
- In the Nasdaq-100 since
- Dec 24, 2012, replacing Apollo Group (APOL), Electronic Arts (EA), Flextronics (FLEX), Green Mountain Coffee Roasters (GMCR), Lam Research (LRCX), Marvell Technology Group (MRVL), Netflix (NFLX), Research in Motion (RIMM), VeriSign (VRSN) and Warner Chilcott (WCRX) · Annual index reconstitution. · All Nasdaq-100 changes
- Analyst coverage
- 1 open price target from 1 firm: Jefferies Approved targets tracked here; see the analyst section below
Regeneron Pharmaceuticals (REGN) is trading up at $796.57 (+1.86%) on NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
Analyst price targets on REGN
One firm's current price target on Regeneron Pharmaceuticals: $930 — 17% above the current $797. Each is tracked to its date and scored the same way a member's call is.
- Jefferies $735 → $930 by Oct 2027 Oct 1, 2026 via Investing.com · Jefferies's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Regeneron Pharmaceuticals revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $4.86B | $5.87B | $5.15B | $6.56B | $8.50B | $16.1B | $12.2B | $13.1B | $14.2B | $14.3B |
| Growth (year over year) | +18.4% | +20.8% | −12.4% | +27.4% | +29.6% | +89.1% | −24.3% | +7.8% | +8.3% | +1.0% |
| Gross profit | $4.67B | $5.67B | $4.91B | $6.15B | — | — | — | — | — | — |
| Gross margin | 96.0% | 96.6% | 95.4% | 93.9% | — | — | — | — | — | — |
| Operating income | $1.33B | $2.08B | $2.53B | $2.21B | $3.58B | $8.95B | $4.74B | $4.05B | $3.99B | $3.58B |
| Operating margin | 27.4% | 35.4% | 49.3% | 33.7% | 42.1% | 55.7% | 38.9% | 30.9% | 28.1% | 24.9% |
| Net income | $895.5M | $1.20B | $2.44B | $2.12B | $3.51B | $8.08B | $4.34B | $3.95B | $4.41B | $4.50B |
| Net margin | 18.4% | 20.4% | 47.5% | 32.3% | 41.3% | 50.2% | 35.6% | 30.1% | 31.1% | 31.4% |
| EPS (diluted) | $7.70 | $10.34 | $21.29 | $18.46 | $30.52 | $71.97 | $38.22 | $34.77 | $38.34 | $41.48 |
| Balance sheet | ||||||||||
| Cash and equivalents | $535.2M | $812.7M | $1.47B | $1.62B | $2.19B | $2.89B | $3.11B | $2.73B | $2.49B | $3.12B |
| Total assets | $6.97B | $8.76B | $11.7B | $14.8B | $17.2B | $25.4B | $29.2B | $33.1B | $37.8B | $40.6B |
| Total liabilities | $2.52B | $2.62B | $2.98B | $3.72B | $6.14B | $6.67B | $6.55B | $7.11B | $8.41B | $9.30B |
| Long-term debt | — | — | — | $0 | $1.98B | $1.98B | $1.98B | $1.98B | $1.98B | $1.99B |
| Shareholders' equity | $4.45B | $6.14B | $8.76B | $11.1B | $11.0B | $18.8B | $22.7B | $26.0B | $29.4B | $31.3B |
| Cash flow | ||||||||||
| Operating cash flow | $1.49B | $1.31B | $2.20B | $2.43B | $2.62B | $7.08B | $5.01B | $4.59B | $4.42B | $4.98B |
| Capital expenditure | $511.9M | $272.6M | $383.1M | $429.6M | $614.6M | $551.9M | $590.1M | $718.6M | $755.9M | $898.4M |
| Free cash flow | $974.0M | $1.03B | $1.81B | $2.00B | $2.00B | $6.53B | $4.42B | $3.88B | $3.66B | $4.08B |
| Dividends paid | — | — | — | — | — | — | — | $0 | $0 | $370.3M |
| Share buybacks | $0 | $0 | $4.40M | $275.9M | $5.85B | $1.65B | $2.08B | $2.23B | $2.60B | $3.44B |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3.72B | $3.79B | $3.03B | $3.68B | $3.75B | $3.88B | $3.61B | $4.29B |
| Growth (year over year) | +10.6% | +10.3% | −3.7% | +3.6% | +0.9% | +2.5% | +19.0% | +16.7% |
| Operating income | $1.18B | $990.2M | $591.7M | $1.08B | $1.03B | $879.9M | $642.9M | $1.29B |
| Operating margin | 31.7% | 26.1% | 19.5% | 29.4% | 27.3% | 22.7% | 17.8% | 30.1% |
| Net income | $1.34B | $917.7M | $808.7M | $1.39B | $1.46B | $844.6M | $727.2M | $1.30B |
| Net margin | 36.0% | 24.2% | 26.7% | 37.9% | 38.9% | 21.7% | 20.2% | 30.2% |
| EPS (diluted) | $11.54 | $8.12 | $7.27 | $12.81 | $13.62 | $7.78 | $6.75 | $12.23 |
| Balance sheet | ||||||||
| Cash and equivalents | $2.01B | $2.49B | $3.09B | $2.00B | $2.51B | $3.12B | $2.96B | $2.46B |
| Total assets | $37.4B | $37.8B | $37.5B | $38.2B | $40.2B | $40.6B | $40.9B | $41.7B |
| Total liabilities | $8.12B | $8.41B | $8.16B | $8.28B | $9.21B | $9.30B | $9.45B | $10.0B |
| Long-term debt | $1.98B | $1.98B | $1.98B | $1.99B | $1.99B | $1.99B | $1.99B | $1.99B |
| Shareholders' equity | $29.3B | $29.4B | $29.4B | $29.9B | $31.0B | $31.3B | $31.4B | $31.7B |
| Cash flow | ||||||||
| Operating cash flow | $1.29B | $1.26B | $1.05B | $1.14B | $1.62B | $1.17B | $1.08B | $813.0M |
| Capital expenditure | $241.9M | $199.6M | $229.3M | $219.0M | $201.4M | $248.7M | $230.6M | $240.2M |
| Free cash flow | $1.05B | $1.06B | $815.8M | $925.4M | $1.42B | $922.0M | $848.3M | $572.8M |
| Dividends paid | $0 | $0 | $93.8M | $92.6M | $91.2M | $92.7M | $97.8M | $96.8M |
| Share buybacks | $735.1M | $973.0M | $1.04B | $1.06B | $664.0M | $671.7M | $794.3M | $1.17B |
From Regeneron Pharmaceuticals's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
Regeneron Pharmaceuticals vs the Health Care sector and the S&P 500
Regeneron Pharmaceuticals's latest reported figures next to the median of the other 59 S&P 500 Health Care companies and of the other 502 S&P 500 companies; each median is taken over the companies with a comparable figure (counts in the footnote). A median is the middle value, not an average, so one very large company does not move it.
| Measure | Regeneron Pharmaceuticals | Health Care (59 other S&P 500 companies) | S&P 500 (502 other companies) |
|---|---|---|---|
| Revenue growth, latest fiscal year | +1.0% | +7.2% | +7.0% |
| Net margin, latest fiscal year | 31.4% | 12.9% | 12.9% |
| Share price change, 1 year | +35.6% | +19.8% | +5.6% |
Regeneron Pharmaceuticals: fiscal year ended December 2025, from its 10-K and 10-Q filings with the SEC. Medians computed October 20, 2026 from each company's latest annual filing (fiscal years ending between July 2025 and September 2026) and our price archive. Prices for every company, Regeneron Pharmaceuticals included, are the last regular-session prices of October 19, 2026; the 1-year change compares that price with each company's last close on or before October 20, 2025. Net margin and price change are our calculations from reported figures. Each median counts only the companies with a comparable figure (sector / S&P 500): revenue growth 59/496, net margin 59/496, 1-year price change 59/490; the reasons below can overlap. 12 are left out of the price figure because our archive holds no comparable close for them. The S&P 500 price figure is the middle company's change, not the index's return.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.
Source: Wikipedia — Regeneron Pharmaceuticals
- Headquarters
- Tarrytown, New York From SEC filings, Oct 2026
Recent News (20)
-
Regeneron reports sustained efficacy for FOP treatment Pasatru
Regeneron reports sustained efficacy for FOP treatment Pasatru
-
Greater San Diego Science and Engineering Fair Students Win 8 Awards at the 76th Regeneron International Science and Engineering Fair SAN DIEGO, Oct. 12, 2026 /PRNewswire/ -- The 76th Regeneron International Science and Engineering Fair (ISEF), the world's largest precollege science and engineering competition, concluded on May 15 w…
-
-
Jefferies raises Regeneron stock price target to $930 on partnership
Jefferies raises Regeneron stock price target to $930 on partnership
-
Regeneron And Sanofi Announce A Win-Win Collaboration Expansion (NASDAQ:REGN) Regeneron And Sanofi Announce A Win-Win Collaboration Expansion (NASDAQ:REGN) Seeking Alpha
-
Regeneron reports 73% response rate for ovarian cancer drug trial
Regeneron reports 73% response rate for ovarian cancer drug trial
-
Upcoming Webinar Hosted by Xtalks: Inside Regeneron's Path to Scientific Intelligence and R&D Efficiency In this free webinar, learn how Regeneron is using a connected laboratory informatics ecosystem to improve R&D efficiency and scientific decision-making. The featured speakers will discuss how integra…
-
Sanofi to pay Regeneron up to $8 billion to add new antibodies under Dupixent partnership
Sanofi to pay Regeneron up to $8 billion to add new antibodies under Dupixent partnership
-
Sanofi gains after expanding Regeneron partnership with $8 billion deal
Sanofi gains after expanding Regeneron partnership with $8 billion deal
-
Regeneron, Sanofi expand alliance with $1 billion upfront deal
Regeneron, Sanofi expand alliance with $1 billion upfront deal
-
-
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
-
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026 TARRYTOWN, N.Y., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2026 financial and operating results on Frida…
-
Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts
Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts
-
Regeneron at Bernstein healthcare forum: growth engines stay in focus
Regeneron at Bernstein healthcare forum: growth engines stay in focus
-
Is Regeneron Stock a Bargain Below $800?
Is Regeneron Stock a Bargain Below $800?
-
-
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
-
-
REGN INVESTOR DEADLINE TOMORROW: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces SAN DIEGO, Sept. 13, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) common stock between August 1, 2025 …
More Health Care stocks
- MRNA Moderna
- MTD Mettler Toledo
- PFE Pfizer
- PODD Insulet Corporation
- RMD ResMed
- RVTY Revvity
- SOLV Solventum
- STE Steris